Chinese Innovative Drug Stocks Rally; Chengdu Xiantao and Aidea Pharma Jump Over 10%

The breadth of the move — beyond one or two names to contract research and manufacturing players like Pharmaron and Medicilon — suggests this is a sector-level repricing rather than a single catalyst. That distinction matters because CRO/CDMO names are typically driven by external demand for outsourced research, while the drug developers move on pipeline or policy news. Whether the buying holds after the session, or fades as it has in past sector rotations, is the open question.